Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease
Copyright © 2017 Elsevier España, S.L.U. All rights reserved..
Cardiovascular disease is a chronic disorder which is usually already at an advanced stage when the first symptoms develop. The fact that the initial clinical presentation can be lethal or highly incapacitating emphasizes the need for primary and secondary prevention. It is estimated that the ratio of patients with good adherence to secondary prevention of cardiovascular disease is low and also decreases gradually over time. The Polypill for secondary prevention of cardiovascular disease is the first fixed-dose combination therapy of salicylic acid, atorvastatin and ramipril approved in Spain. The purpose of this consensus document was to define and recommend, through the evidence available in the literature and clinical expert opinion, the impact of treatment adherence in the secondary prevention of cardiovascular disease and the use of the Polypill in daily clinical practice as part of a global strategy including adjustments in patient lifestyle. A RAND/UCLA methodology based on scientific evidence, as well as the collective judgment and clinical expertise of an expert panel was used for this assessment. As a result, a final report of recommendations on the impact of the lack of adherence to treatment of secondary prevention of cardiovascular disease and the effect of using a Polypill in adherence of patients was produced. The recommendations included in this document have been addressed to all those specialists, cardiologists, internists and primary care physicians with competence in prescribing and monitoring patients with high and very high cardiovascular risks.
| Errataetall: |
CommentIn: Med Clin (Barc). 2017 Oct 23;149(8):367. - PMID 28476450 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:148 |
|---|---|
| Enthalten in: |
Medicina clinica - 148(2017), 3 vom: 09. Feb., Seite 139.e1-139.e15 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Documento de consenso del uso clínico de la Polypill en la prevención secundaria del riesgo cardiovascular |
|---|
| Beteiligte Personen: |
González-Juanatey, José Ramón [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2017 Date Revised 02.12.2018 published: Print-Electronic CommentIn: Med Clin (Barc). 2017 Oct 23;149(8):367. - PMID 28476450 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2016.10.031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM267278691 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM267278691 | ||
| 003 | DE-627 | ||
| 005 | 20231224220330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2016.10.031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0890.xml |
| 035 | |a (DE-627)NLM267278691 | ||
| 035 | |a (NLM)27993410 | ||
| 035 | |a (PII)S0025-7753(16)30565-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a González-Juanatey, José Ramón |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease |
| 246 | 3 | 3 | |a Documento de consenso del uso clínico de la Polypill en la prevención secundaria del riesgo cardiovascular |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Med Clin (Barc). 2017 Oct 23;149(8):367. - PMID 28476450 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Cardiovascular disease is a chronic disorder which is usually already at an advanced stage when the first symptoms develop. The fact that the initial clinical presentation can be lethal or highly incapacitating emphasizes the need for primary and secondary prevention. It is estimated that the ratio of patients with good adherence to secondary prevention of cardiovascular disease is low and also decreases gradually over time. The Polypill for secondary prevention of cardiovascular disease is the first fixed-dose combination therapy of salicylic acid, atorvastatin and ramipril approved in Spain. The purpose of this consensus document was to define and recommend, through the evidence available in the literature and clinical expert opinion, the impact of treatment adherence in the secondary prevention of cardiovascular disease and the use of the Polypill in daily clinical practice as part of a global strategy including adjustments in patient lifestyle. A RAND/UCLA methodology based on scientific evidence, as well as the collective judgment and clinical expertise of an expert panel was used for this assessment. As a result, a final report of recommendations on the impact of the lack of adherence to treatment of secondary prevention of cardiovascular disease and the effect of using a Polypill in adherence of patients was produced. The recommendations included in this document have been addressed to all those specialists, cardiologists, internists and primary care physicians with competence in prescribing and monitoring patients with high and very high cardiovascular risks | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a Adherencia | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Combination therapy | |
| 650 | 4 | |a Enfermedad cardiovascular | |
| 650 | 4 | |a Polypill | |
| 650 | 4 | |a Prevención | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Recomendaciones | |
| 650 | 4 | |a Recommendations | |
| 650 | 4 | |a Tratamiento combinado | |
| 650 | 7 | |a Cardiovascular Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Atorvastatin |2 NLM | |
| 650 | 7 | |a A0JWA85V8F |2 NLM | |
| 650 | 7 | |a Ramipril |2 NLM | |
| 650 | 7 | |a L35JN3I7SJ |2 NLM | |
| 650 | 7 | |a Salicylic Acid |2 NLM | |
| 650 | 7 | |a O414PZ4LPZ |2 NLM | |
| 700 | 1 | |a Mostaza, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Lobos, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Abarca, Benjamín |e verfasserin |4 aut | |
| 700 | 1 | |a Llisterri, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Baron-Esquivias, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Galve, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Lidón, Rosa María |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Moll, Francisco Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Pedro Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Suárez, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Millán, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Pallares, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Alemán, José Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Egocheaga, Isabel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 148(2017), 3 vom: 09. Feb., Seite 139.e1-139.e15 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:148 |g year:2017 |g number:3 |g day:09 |g month:02 |g pages:139.e1-139.e15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2016.10.031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 148 |j 2017 |e 3 |b 09 |c 02 |h 139.e1-139.e15 | ||